Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-11-06

FDA Approved: QUINAPRIL AND HYDROCHLOROTHIAZIDE 10/12.5 — Supplemental Application (Cipla USA Inc.)

View source ↗

Summary

FDA approved a supplemental application for quinapril and hydrochlorothiazide fixed-dose combinations in three dosage strengths (10/12.5, 20/12.5, 20/25) from C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • QUINAPRIL AND HYDROCHLOROTHIAZIDE 10/12.5 (Quinapril and Hydrochlorothiazide)
  • QUINAPRIL AND HYDROCHLOROTHIAZIDE 20/12.5 (Quinapril and Hydrochlorothiazide)
  • QUINAPRIL AND HYDROCHLOROTHIAZIDE 20/25 (Quinapril and Hydrochlorothiazide)

Snippet

SUPPL AP for QUINAPRIL AND HYDROCHLOROTHIAZIDE 10/12.5 (QUINAPRIL AND HYDROCHLOROTHIAZIDE 10/12.5)